Clinical Trials Logo
  1. Home
  2. Diabetes Mellitus, Type 2
  3. NCT02601729

Reimbursement Study of Continuous Glucose Monitoring in Belgium — RESCUE  

Diabetes, Type 1 Clinical Trial

Official title:
Clinical Impact of RT-CGM Reimbursement in Belgium: a Multicenter Real-life Observational Study

Clinical Trial Summary

Type 1 diabetes mellitus (T1DM) is an autoimmune disease caused by an immune mediated destruction of the pancreatic β-cells. Once the pancreas has been depleted of a critical mass of β-cells the need for exogenous insulin therapy emerges. Several methods exist to administer insulin. An alternative way to administer insulin is by means of continuous subcutaneous insulin infusions (CSII) or insulin-pump therapy.The frequent execution of self-monitoring of blood glucose (SMBG) accomplished by a capillary finger-stick test is essential in the management of diabetes, but this is very limited and also lacks information about rising or falling trends in the actual glycaemia. A solution for this is the use of a Real-Time Continuous Glucose Monitoring (RT-CGM) device. Contrary to SMBG, RT-CGM measures glycaemia 24 hours a day, provides information about glucose direction and rate of change during multiple days a week. Since September 2014, RT-CGM is reimbursed in Belgium for a selected group of type 1 diabetic patients by means of a so-called "CGM convention". The main objective of the study is to evaluate the impact of real time continuous glucose monitoring reimbursement on real-life clinical care parameters of type 1 diabetic patients in Belgium after 12 and 24 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02601729
Study type Observational
Source KU Leuven
Contact
Status Completed
Phase
Start date September 2014
Completion date January 18, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT01805414 - Breakfast Nutrition and Inpatient Glycemia N/A
Terminated NCT00700622 - Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks Phase 3
Completed NCT00308737 - Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes Phase 3
Completed NCT02657213 - Study of Insulin Pump in Prevention of Low Glucose Events in Adults With Type 1 Diabetes at Risk of Severe Hypoglycemia N/A
Terminated NCT01350102 - The Relationship of Hemoglobin A1c and Diabetic Wound Healing Phase 4
Withdrawn NCT03494010 - Hybrid Closed-Loop Insulin Delivery System in Type 1 Diabetes Candidates for a Living Donor Kidney Transplant
Completed NCT02214719 - Edmonton Automated Sugar Intelligence - Intelligent Diabetes Management, EASI-IDM, App Program to Assist Diabetes Care N/A